Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

No abstract is available for this paper.

• Publication year

  2002

• Venue

  AIDS (London)

• Publication date

  2002-12-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002030-200212060-00010PMID 12461419
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Categorical Data Analysis

  2003cited by this paper
• Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

  2002cited by this paper
• Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial)

  2002cited by this paper
• Altered Fat Distribution in HIV‐Positive Men on Nucleoside Analog Reverse Transcriptase Inhibitor Therapy

  2001cited by this paper
• Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

  2001cited by this paper
• Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

  2001cited by this paper
• Stavudine Versus Zidovudine and the Development of Lipodystrophy

  2001cited by this paper
• Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

  2001cited by this paper
• Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.

  2001cited by this paper
• Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

  2000influential reference
• Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection

  2000cited by this paper
• Sonographic assessment of regional fat in HIV-1-infected people.

  2000cited by this paper
• Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

  2000cited by this paper
• Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study

  2000cited by this paper
• Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.

  1999cited by this paper
• Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy.

  1999influential reference
• Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

  1999influential reference
• Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

  1999cited by this paper
• Lipodystrophy in patients naive to HIV protease inhibitors.

  1999cited by this paper
• A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

  1999cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

  1998influential reference
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

  1998cited by this paper
• Mitochondrial genetics: a paradigm for aging and degenerative diseases?

  1992cited by this paper
• FAST TRACK: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome

  year unknowncited by this paper

• The urgent need for newer drugs in routine HIV treatment in Africa: the case of Ghana

  2025cites this paper
• Developments in Exploring Fungal Secondary Metabolites as Antiviral Compounds and Advances in HIV-1 Inhibitor Screening Assays

  2023cites this paper
• Metabolic Consequences of Antiretroviral Therapy

  2022cites this paper
• Genetic and cytometric analyses of subcutaneous adipose tissue in patients with hemophilia and HIV-associated lipodystrophy

  2022cites this paper
• Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients

  2021cites this paper
• L-Carnitine and Acylcarnitines: Mitochondrial Biomarkers for Precision Medicine

  2021cites this paper
• Antiretroviral therapy associated lipodystrophy; learning from the past

  2021cites this paper
• Associations Between Central Obesity and Lifelong Antiviral Therapy in Adults Living With HIV Acquired From Early Childhood

  2021cites this paper
• PS-SiZer map to investigate significant features of body-weight profile changes in HIV infected patients in the IeDEA Collaboration

  2020cites this paper
• Lipodystrophic syndrome of HIV and associated factors: a study in a university hospital.

  2020cites this paper
• HIV_A_275314 507..524

  2020influential citation
• Lipodystrophic syndrome of HIV and associated factors: a study in a university hospital

  2020cites this paper
• Antiretroviral Therapy-Associated Metabolic Complications: Review of the Recent Studies

  2020cites this paper
• Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors.

  2020cites this paper
• SiZer Map to investigate significant features of body-weight profile changes in HIV infected patients in the IeDEA Collaboration

  2019cites this paper
• Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy.

  2019cites this paper
• Current antiretroviral drugs for human immunodeficiency virus infection: review article

  2019cites this paper
• Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race

  2018cites this paper
• Electrocardiographic Abnormalities Among HIV Infected Adults Attending The Comprehensive Care Center At Kenyatta National Hospital

  2018cites this paper
• Clinical and color Doppler ultrasound evaluation of polyacrylamide injection in HIV patients with severe facial lipoatrophy secondary to antiretroviral therapy

  2017cites this paper
• Chapter 6 The Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients

  2017cites this paper
• Dyslipidemia in HIV Infected Children and Adolescents on Highly Active Antiretroviral Therapy in Abuja, Nigeria

  2017cites this paper
• Lipodystrophy among HIV-Infected Patients Attending Care and Treatment Clinics in Dar es Salaam

  2017cites this paper
• Measurement of Abdominal Fat Changes and Predictors of Excess Fat Gain in HIV-Infected Individuals Initiating Therapy

  2016cites this paper
• HIV Infection and Diabetes

  2016cites this paper
• Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report

  2016cites this paper
• Penalized spline modeling of the ex-vivo assays dose-response curves and the HIV-infected patients' bodyweight change

  2015cites this paper
• Lipodystrophy among Children Infected with Human Immunodeficiency Virus and on Antiretroviral Treatment in Ouagadougou

  2015cites this paper
• Cardiovascular disease in HIV patients: from bench to bedside and backwards

  2015cites this paper
• Characterisation of Clinical Epidemiological Profie of Patients with Facial Lipoatrophy, Living with Aids, Submitted to Facial Filling with Polymethylmethacrylate

  2015cites this paper
• Heterogeneity in Nutritional and Lipid Profiles in Children and Adolescents with Human Immunodeficiency Virus Treated with Highly Active Antiretroviral Therapy

  2015cites this paper
• HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings

  2015cites this paper
• The successful use of lipectomy in the management of airway obstruction in a woman with HIV-associated lipodystrophy

  2015cites this paper
• The Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients

  2015cites this paper
• Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

  2015cites this paper
• HIV therapy-the state of art.

  2015influential citation
• Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

  2015cites this paper
• PhD thesis Non-HIV determinants of outcome in Danish HIV-infected patients: Impact of study participation, body fat distribution and family-related factors

  2015cites this paper
• HIV and Metabolic, Body, and Bone Disorders: What We Know From Low- and Middle-Income Countries

  2014cites this paper
• Efficacy and safety of once‐daily maraviroc plus ritonavir‐boosted darunavir in pretreated HIV‐infected patients in a real‐life setting

  2014cites this paper
• HIV-associated lipodystrophy: a review from a Brazilian perspective

  2014cites this paper
• Breast hypertrophy and gynaecomastia in HIV-associated lipodystrophy, a problematic side-effect of life-saving antiretroviral therapy

  2014cites this paper
• An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes

  2014cites this paper
• ASSOCIATION BETWEEN STAVUDINE ADMINISTRATION WITH LIPODYSTROPHY AND DYSLIPIDEMIA AMONG HIV-INFECTED PATIENTS IN DR. KARIADI HOSPITAL SEMARANG

  2014cites this paper
• The role of side effects in shifting patients from first line to second line ART at Nthabiseng Clinic in Soweto, Johannesburg

  2014cites this paper
• Medición de concentraciones plasmáticas de antirretrovirales en niños con infección por el virus de la inmunodeficiencia humana tipo 1

  2014cites this paper
• Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS

  2013cites this paper
• HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon.

  2013cites this paper
• Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face

  2013cites this paper
• Evaluation of side effects events peripheral neuropathy and lipodystrophy in patients with HIV/AIDS who used stavudine in antiretroviral regimens

  2013cites this paper
• Investigation of lipodystrophy syndrome in a multicentre prospective cohort of HIV-infected children and adolescents living in Europe

  2013cites this paper
• QUANTITATIVE ASSESSMENT OF THE PREVALENCE OF MITOCHONDRIAL TOXICITY IN HIV/AIDS PATIENTS INITIATED ON A STAVUDINE CONTAINING REGIMEN IN MOUNT AYLIFF HOSPITAL ARV CLINIC

  2013cites this paper
• Reasons for Change of Anti-Retroviral Therapy (ART) Drugs: Local Experience

  2013cites this paper
• Longer Prior Exposure to Zidovudine/Lamivudine-Containing Combination Antiretroviral Therapy, Age, and Male Gender Are Each Associated With Reduced Subcutaneous Adipose Tissue

  2012cites this paper
• Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy.

  2012cites this paper
• Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study

  2012cites this paper
• Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency Virus-Related Facial Lipoatrophy: Results of the LIPOPHILL Open-Label Study

  2012cites this paper
• Metabolic Complications Associated with HIV Protease Inhibitor Therapy

  2012cites this paper
• Chapter 11 – Overview of antiretroviral therapy

  2012cites this paper
• Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection

  2012cites this paper
• BODY FAT MALDISTRIBUTION AMONG HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS ATTENDING CARE AND TREATMENT CLINICS IN DAR ES SALAAM MUNICIPAL HOSPITALS

  2012cites this paper
• Body Fat Abnormality in HIV-Infected Children and Adolescents Living in Europe: Prevalence and Risk Factors

  2012cites this paper
• Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA

  2012influential citation
• Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care

  2011cites this paper
• Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes.

  2011cites this paper
• Why should we still care about the stavudine dose

  2011cites this paper
• The Role of Toxicity-Related Regimen Changes in the Development of Antiretroviral Resistance

  2011cites this paper
• Drug combinations for HIV: what’s new?

  2011cites this paper
• Estudio del sistema musculoesquelético mediante resonancia magnética en la valoración del síndrome de lipodistrofia en pacientes infectados por el virus de la inmunodeficiencia humana

  2011cites this paper
• Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.

  2011cites this paper
• Lipodystrophy, insulin resistance, and adiponectin concentration in HIV-infected children and adolescents.

  2011cites this paper
• Combination antiretroviral therapy -associated lipodystrophy : insights into pathogenesis and treatment

  2011cites this paper
• Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy

  2011cites this paper
• From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir

  2011cites this paper
• Estudo dos fatores de risco para aterosclerose em pacientes HIV positivos que fazem uso de HAART e que apresentam doença periodontal

  2011cites this paper
• Risk Factors in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients Undergoing Antiretroviral Therapy in the State of Pernambuco, Brazil: A Case–Control Study

  2010cites this paper
• Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.

  2010cites this paper
• New and emerging agents in the management of lipodystrophy in HIV-infected patients

  2010cites this paper
• Approach to Dyslipidemia, Lipodystrophy, and Cardiovascular Risk in Patients with HIV Infection

  2010cites this paper
• [New and "old" antiretroviral drugs in Pediatrics: new doses, formulations and associations].

  2010cites this paper
• Nucleoside analog stavudine depletes mitochondrial DNA with no organelle loss in mouse oocytes.

  2010cites this paper
• New and emerging agents in the management of lipodystrophy in HIV-infected patients

  2010cites this paper
• Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation.

  2010cites this paper
• Pediatric antiretroviral therapy

  2010cites this paper
• The Role of Mitochondria in HIV Infection and Its Treatment

  2010cites this paper
• Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease

  2010cites this paper
• Patient Retention and Adherence to Antiretrovirals in a Large Antiretroviral Therapy Program in Nigeria: A Longitudinal Analysis for Risk Factors

  2010cites this paper
• Increased risk for type 2 diabetes mellitus with HIV-1 infection

  2010cites this paper
• Pharmacogenetics of adverse effects due to antiretroviral drugs.

  2010cites this paper
• Strategies to limit the metabolic complications of treatment for HIV infection

  2009cites this paper
• Adiponectin and Leptin Levels in Chinese Patients with HIV-Related Lipodystrophy: A 30-Month Prospective Study

  2009cites this paper
• Racial Differences in Changes of Metabolic Parameters and Body Composition in Antiretroviral Therapy-Naive Persons Initiating Antiretroviral Therapy

  2009cites this paper
• Safety Aspects of Antiretroviral Therapy for Management of HIV Infection

  2009cites this paper
• Stavudine in antiretroviral therapy: is this the end?

  2009cites this paper
• Disorders of body fat distribution in HIV-1-infected patients.

  2009cites this paper
• Mitochondrial DNA Depletion and Respiratory Chain Activity in Primary Human Subcutaneous Adipocytes Treated with Nucleoside Analogue Reverse Transcriptase Inhibitors

  2009cites this paper
• Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy

  2009cites this paper
• Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.

  2009cites this paper
• Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

  2009cites this paper
• Comparison of Nucleoside Reverse Transcriptase Inhibitor Use as Part of First-Line Therapy in a Serbian and a UK HIV Clinic

  2009cites this paper